Abstract：【Objective】 To explore the efficacy and safety of everolimus combined with fulvestrant in the treatment of estrogen receptor-positive advanced breast cancer patients. 【Methods】 Seventy-three patients with estrogen receptor-positive advanced breast cancer admitted to our hospital were selected as the research objects, and they were randomly divided into the control group and the observation group. A total of 36 patients in the control group were treated with fulvestrant as a single agent. A total of 37 patients in the treatment group were treated with everolimus combined with fulvestrant. The treatment effect, progression-free survival (PFS) and the occurrence of adverse reactions of the two groups of patients were observed in the two groups. 【Results】 The objective response rate (ORR) was 18.92% (7/37) in the observation group and 11.11%(4/36) in the control group, which there was no significant difference between two groups (P>0.05). The disease control rate (DCR) of the treatment group was 81.08% (30/37), which was significantly higher than that of the control group 58.33% (21/36) (P<0.05). The median PFS of the control group was 5 months (95%CI:1.381~8.619) and the median PFS of the observation group was 10 months (95%CI:7.102~12.898). The PFS of the observation group was significantly longer than that of the control group (P<0.05). The incidence of abnormal liver function, bone marrow suppression, oral mucositis, skin rash and gastrointestinal reactions in the observation group was significantly higher than that in the control group (P<0.05). 【Conclusion】 The efficacy of everolimus combined with fulvestrant in the treatment of estrogen receptor-positive advanced breast cancer patients is significantly better than that of fulvestrant monotherapy, however, it should be noted that the incidence of adverse reactions is also high.
任晓红, 赵妮霞. 依维莫司联合氟维司群治疗雌激素受体阳性晚期乳腺癌的疗效及安全性[J]. 医学临床研究, 2022, 39(5): 729-731.
REN Xiao-hong, ZHAO Ni-xia. Efficacy and Safety of Everolimus Combined with Fulvestrant in the Treatment of Estrogen Receptor-positive Advanced Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 729-731.
[1] NAJIM O, SEGHERS S, SERGOYNNE L, et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer:A systematic review and meta-analysis of randomized and non-randomized trials[J].Biochim Biophys Acta Rev Cancer,2019,1872(2):188315.
[2] MASSARWEH S, ROMOND E, BLACK EP, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [J].Breast Cancer Res Treat,2014,143(2):325-332.
[3] BOÉR K. Fulvestrant in advanced breast cancer:evidence to date and place in therapy[J].Ther Adv Med Oncol,2017,9(7):465-479.
[4] ROYCE M, BACHELOT T, VILLANUEVA C, et al. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:a clinical trial[J].JAMA Oncol.2018,4(7):977-984.
[5] 冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C].第三届中国肿瘤内科大会教育集暨论文集,2009:141-143.
[6] GNANT M. Overcoming endocrine resistance in breast cancer:importance of mTOR inhibition[J].Expert Rev Anticancer Ther,2012,12(12):1579-1589.
[7] KORNBLUM N, ZHAO F, MANOLA J, et al. Randomized phase Ⅱ trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy:results of PrE0102[J].J Clin Oncol,2018,36(16):1556-1563.
[8] SCHMID P, ZAISS M, HARPER-WYNNE C, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer:the manta phase 2 randomized clinical trial[J].JAMA Oncol,2019,5(11):1556-1563.
[9] AAPRO M, ANDRE F, BLACKWELL K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus:focus on breast cancer[J].Ann Oncol,2014,25(4):763-773.
[10] 张霖惠,李惠平,邵彬,等. 依维莫司治疗激素受体阳性、HER2阴性进展期乳腺癌的疗效及安全性研究[J].癌症进展,2019,17(3):295-300.
2022, Vol. 39 
